Core Insights - Expert Systems Inc. continues to support Traws Pharma as it initiates Phase 2 clinical studies of Ratutrelvir (TRX01), an oral antiviral for newly diagnosed COVID-19 patients [1][5] Company Overview - Expert Systems Inc. is a life sciences accelerator focused on advancing precision therapeutics through an AI/ML-enabled platform that integrates drug design, predictive pharmacology, and regulatory strategy [6][7] Product Development - Ratutrelvir (TRX01) shows broad-spectrum in vitro activity against various SARS-CoV-2 strains and has a unique formulation that does not require ritonavir, thus avoiding drug-drug interactions that affect about 20% of COVID patients [3][4] - In Phase 1 studies, a daily oral dose of 600 mg maintained plasma concentrations approximately 13 times above the effective concentration (EC50) for the entire 10-day course, with trough levels above EC90, crucial for preventing viral rebound [4][5] - The Phase 2 program includes a non-inferiority trial against PAXLOVID® and a trial for populations ineligible for PAXLOVID®, addressing a significant unmet need [8] Strategic Collaboration - Expert Systems will provide ongoing strategic, scientific, and technological support as Ratutrelvir progresses through human efficacy studies, highlighting its capability to de-risk innovation and accelerate clinical translation [5]